Stereotactic ablative radiotherapy for small lung tumors with a moderate dose: Favorable results and low toxicity

Strahlentherapie und Onkologie

Volumn 189, Issue 1, 2013, Pages 33-40

  Duncker Rohr, V ^a   Nestle, U ^a   Momm, F ^b   Prokic, V ^a   Heinemann, F ^a   Mix, M ^a   Reusch, J ^a   Messmer, M B ^a   Marschner, N ^c   Waller, C F ^a   Weber, W A ^a   Grosu, A L ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Klinikum Offenburg   (Germany)

^c Praxis für Interdisziplinäre Onkologie und Hämatologie Freiburg   (Germany)

Author keywords

Metastasis; Non small cell lung cancer; Optimum dose schedule; Stereotactic ablative radiotherapy; Toxicity

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LUNG BIOPSY; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MALE; RADIATION DOSE; RADIATION INJURY; STEREOTACTIC ABLATIVE BODY RADIOTHERAPY; STEREOTACTIC RADIOSURGERY; TREATMENT PLANNING;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; LUNG VOLUME MEASUREMENTS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOSURGERY;

EID: 84871748178     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-012-0224-y     Document Type: Article

References (42)

1. Loo BW et al (2011) Stereotactic ablative radiotherapy: what's in a name? Practical Radiat Oncol 1:38-39
2. Crabtree TD et al (2010) Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 140:377-386
3. Grills IS et al (2010) Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 28:928-935
4. Haasbeek CJ et al (2010) Stage I nonsmall cell lung cancer in patients aged > or = 75 years: outcomes after stereotactic radiotherapy. Cancer 116:406-414
5. Lagerwaard FJ et al (2008) Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 70:685-692
6. Nguyen NP et al (2008) Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma. Cancer Treat Rev 34:719-727
7. Onishi H et al (2010) Stereotactic Body Radiotherapy (SBRT) for operable stage i non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys 81:1352-1358
8. Timmerman RD et al (2009) Local surgical, ablative, and radiation treatment of metastases. CA Cancer J Clin 59:145-170
9. Palma D et al (2010) Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol 28:5153-5159
10. Timmerman R et al (2007) Optimizing dose and fractionation for stereotactic body radiation therapy. Normal tissue and tumor control effects with large dose per fraction. Front Radiat Ther Oncol 40:352-365
11. Onishi H et al (2007) Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2 [7 Suppl 3]:S94-S100
12. Hiraoka M, Nagata Y (2004) Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the Japanese experience. Int J Clin Oncol 9:352-355
13. Zhang J et al (2011) Which is the optimal biologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis. Int J Radiat Oncol Biol Phys 81:305-316
14. McGarry RC et al (2005) Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys 63:1010-1015
15. Guckenberger M et al (2009) Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys 74:47-54
16. Wurstbauer K et al (2010) Non-small cell lung cancer in stages I-IIIB: Long-term results of definitive radiotherapy with doses >/= 80 Gy in standard fractionation. Strahlenther Onkol 186:551-557
17. Chang BK, Timmerman RD (2007) Stereotactic body radiation therapy: a comprehensive review. Am J Clin Oncol 30:637-644
18. Dahele M et al (2009) Stereotactic radiation therapy for inoperable, early-stage non-small-cell lung cancer. CMAJ 180:1326-1328
19. Heinzerling JH, Kavanagh B, Timmerman RD (2011) Stereotactic ablative radiation therapy for primary lung tumors. Cancer J 17:28-32
20. Siva S, MacManus M, Ball D (2010) Stereotactic radiotherapy for pulmonary oligometastases: a systematic review. J Thorac Oncol 5:1091-1099
21. Zimmermann FB et al (2005) Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancer. Lung Cancer 48:107-114
22. Lammering G et al (2010) The use of FDG-PET to target tumors by radiotherapy. Strahlenther Onkol 186:471-481
23. Hodapp N et al (2009) The Freiburg patient positioning and fixation concept for precision radiotherapy. Strahlenther Onkol 185:126
24. Boda-Heggemann J et al (2011) kV cone-beam CT-based IGRT: a clinical review. Strahlenther Onkol 187:284-291
25. Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
26. Young H et al (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35:1773-1782
27. NIH and NCI (2009) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. available on http://ctep.cancer.gov/protocolDevelopment/ electronic-applications/ctc.htm#ctc-40
28. Andratschke N et al (2011) Stereotactic radiotherapy of histologically proven inoperable stage I non-small cell lung cancer: patterns of failure. Radiother Oncol 101:245-249
29. Wulf J et al (2004) Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys 60:186-196
30. Timmerman R et al (2003) Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 124:1946-1955
31. Bradley JD et al (2010) Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant. Int J Radiat Oncol Biol Phys 77:1146-1150
32. Oshiro Y et al (2010) Stereotactic body radiotherapy for lung tumors at the pulmonary hilum. Strahlenther Onkol 186:274-279
33. Baardwijk A van et al (2011) What is the radiation dose needed to eradicate stage I NSCLC with Stereotactic Radiotherapy (SBRT)? J Thorac Oncol 6:544
34. Hoppe BS et al (2008) Acute skin toxicity following stereotactic body radiation therapy for stage I non-small-cell lung cancer: who's at risk? Int J Radiat Oncol Biol Phys 72:1283-1286
35. Borst GR et al (2009) Radiation pneumonitis in patients treated for malignant pulmonary lesions with hypofractionated radiation therapy. Radiother Oncol 91:307-313
36. Jin JY et al (2009) Impact of fraction size on lung radiation toxicity: hypofractionation may be beneficial in dose escalation of radiotherapy for lung cancers. Int J Radiat Oncol Biol Phys 76:782-788
37. Takeda A et al (2010) Early graphical appearance of radiation pneumonitis correlates with the severity of radiation pneumonitis after stereotactic body radiotherapy (SBRT) in patients with lung tumors. Int J Radiat Oncol Biol Phys 77:685-690
38. Hamamoto Y et al (2011) Relationship between pretreatment FDG uptake and local control after stereotactic body radiotherapy in stage I non-small-cell lung cancer: the preliminary results. Jpn J Clin Oncol 41:543-547
39. Nestle U et al (2009) Biological imaging in radiation therapy: role of positron emission tomography. Phys Med Biol 54:R1-R25
40. Waarde A van et al (2004) Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med 45:695-700
41. Vansteenkiste J, Dooms C (2007) Positron emission tomography in nonsmall cell lung cancer. Curr Opin Oncol 19:78-83
42. Baardwijk A van et al (2008) Individualized radical radiotherapy of non-small-cell lung cancer based on normal tissue dose constraints: a feasibility study. Int J Radiat Oncol Biol Phys 71:1394-1401